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High affinity cyclic AMP phosphodiesterase ctivity in preparations of acini isolated from mammary 
tissue of lactating rats is shown to be stimulated by the addition of physiological concentrations of insulin 
to incubations of acini in vitro. This effect is expressed specifically on membrane-associated 
phosphodiesterase nd occurs in the absence of concurrent protein synthesis. The possible functional role 
of this aspect of insulin’s action on mammary tissue is discussed and compared with the well-known 
reversal by this hormone of the effects of lipolytic agents in adipose tissue and liver. 
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1. INTRODUCTION consequent activity change, of target proteins 
[7-91. 
Acute regulation of cellular metabolism in 
response to hormonal and other stimuli is com- 
monly mediated by changes in the cytosolic con- 
centration of either cyclic AMP or Ca2+ with 
possibilities for interaction between these two se- 
cond messengers [ 1,2]. Current hypotheses link the 
activation of Ca*+ or cyclic AMP-dependent pro- 
tein kinases with the final delivery system of these 
second messengers [3]. The identity of the second 
messenger for the action of insulin, however, has 
not yet been firmly established. There is long- 
standing evidence of changes in the phosphoryla- 
tion status of certain target enzymes in adipocytes 
[4,5] and hepatocytes [6] following exposure to in- 
sulin in vitro. More recent data implicate a small 
molecular mass acid-stable chemical messenger, 
liberated from the plasma membrane on treatment 
with insulin, in the mediation between the binding 
of insulin to its plasma membrane receptors and 
the phosphorylation/dephosphorylation, with 
One such target protein is a high affinity form of 
cyclic AMP phosphodiesterase (EC 3.1.4.17). In 
adipocytes [lo] and hepatocytes [ 1 l] the activity of 
this enzyme in a membrane fraction is enhanced by 
treatment with insulin (review [29]). In adipocytes, 
the insulin-sensitive phosphodiesterase occurs in 
both plasma membrane and endoplasmic reti- 
culum [ 10,12,29]; also in this cell type, the involve- 
ment of the low molecular mass chemical mediator 
in insulin-dependent activation of high affinity 
cyclic AMP phosphodiesterase has been reported 
[ 131. All but one report [14] of insulin-sensitive 
phosphodiesterase in the hepatocyte locate it on 
the plasma membrane. Authors in [IS] claim that 
its insulin-activation in hepatocyte plasma mem- 
branes is accompanied by a cyclic AMP-dependent 
phosphorylation which is mediated not by soluble 
cyclic AMP-dependent protein kinase but by a 
membrane-associated protein kinase which, it is 
postulated, may be in a close stoichiometric asso- 
ciation with the insulin receptor. 
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may be involved in the response of susceptible cells 
to insulin. In the light of its effect on cyclic AMP 
phosphodiesterase, it remains a possibility that one 
such mechanism, particularly associated with the 
antagonism of the effects of catecholamines and 
glucagon, is the lowering of cyclic AMP levels in 
select intracellular compartments. 
We describe here an investigation of the 
response to insulin challenge of the cyclic AMP 
phosphodiesterase activity in acini isolated from 
lactating rat mammary gland. These studies were 
undertaken firstly to extend the generality of the 
observations reported using adipocytes and 
hepatocytes and secondly because of the unusual 
profile of hormone-response in this mammary 
tissue preparation [17] characterized by sensitivity 
to insulin but apparently not to adrenaline or 
glucagon. 
2. EXPERIMENTAL 
2.1. Preparations and procedures 
Acini were prepared from the inguinal/ab- 
dominal mammary glands of mid-lactating (9-l 1 
days post-delivery) Wistar rats by collagenase 
digestion as in [18] and [17]. They were incubated 
in a Krebs-Henseleit bicarbonate buffer (pH 7.4) 
containing 4% (w/v) dialyzed bovine serum 
albumin and 2% (w/v) dialyzed Ficoll at 37°C in 
the presence or absence of additions as indicated. 
Each incubation vessel (25 ml stoppered polycar- 
bonate conical flask) contained 2 ml medium, an 
OJCO2 mixture (95%/5%) in the gas phase, and 
was shaken at 160 excursions per min in a shaking 
water bath. At time zero, 0.5 ml of a suspension 
containing about 250 mg wet wt of acini was added 
to the flask. After 60 min, the entire contents of 
each flask were homogenized in a glass-glass 
Potter-Elvehjem-type homogenizer with a motor 
driven pestle (1000 rpm) at 0°C for 45 s. 
The resulting homogenate was either used direct- 
ly for assays or subjected to centrifugation at 
178 000 x g for 2 min at 4°C in a Beckman Airfuge 
to sediment a crude particulate fraction, which was 
then resuspended to the original homogenate 
volume, in 40 mM Tris-HCl (pH 8.0) containing 
4.3 mM 2-mercaptoethanol. In a given experiment, 
each experimental condition (control, plus insulin, 
etc.) was represented by duplicate flasks. Each ex- 
periment was performed using a different prepara- 
tion of acini. 
2.2. Assay methods 
Suitable dilutions of unfractionated acini 
homogenates or of particulate fractions were 
assayed in duplicate at 30°C for cyclic AMP 
phosphodiesterase activity at 1 PM cyclic AMP us- 
ing the two-step procedure in [ 191. 5 ’ -Nucleotidase 
(EC 3.1.3.5) was assayed at 37°C as in [20] and the 
protein content of particulate fraction suspensions 
was measured by the dye-binding method in [21]. 
It was not possible to determine the mammary cell 
protein content of homogenate samples because of 
the presence in them of 4% albumin. Phosphodie- 
sterase activities are expressed, therefore, either as 
pU per ml homogenate or per mU 5 ‘-nucleotidase 
activity. One unit of enzyme activity is that which 
generates 1 pmol product/min under the defined 
conditions of assay. 
2.3. Chemicals and radiochemicals 
Cyclic [8-3H]AMP (spec. act. 28 Ci/mmol) was 
purchased from Amersham International (Amer- 
sham, England). Dowex 1x8-400 (chloride form), 
cyclic AMP, bovine serum albumin (fraction V, 
essentially fatty acid-free) cycloheximide and 
Ficoll type 400 were from Sigma (Poole, England). 
The Bradford protein reagent was from Bio-Rad 
(Watford, England) and collagenase was Wor- 
thington CLS III (lot no. 41S130). Insulin (por- 
cine, 23.6 U/mg) was a generous gift from the 
Boots Co. Ltd (Nottingham, England). All other 
chemicals were of Analar purity from BDH Ltd 
(Poole, England). 
3. RESULTS 
When mammary acini were incubated in the 
presence of insulin, under conditions which have 
been shown to permit the expression of an insulin- 
stimulation of lipogenesis [171, high affinity cyclic 
AMP phosphodiesterase activity was increased 
relative to that of the insulin-free control. This ef- 
fect was observed only when phosphodiesterase ac- 
tivity of particulate fractions was assayed; an in- 
crease was not detectable in unfractionated 
homogenates of insulin-treated acini (table 1). No 
effects of insulin either on unfractionated acini or 
particulate fractions were seen when phosphodie- 
sterase activity was measured using 1OOpM cyclic 
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Table 1 
February 1984 
Effect of insulin and cycloheximide on high affinity cyclic AMP phosphodiesterase activity in rat mammary acini 
Additions No. of 
experi- 
ments 
‘Low K,’ cyclic AMP phosphodiesterase activity 
Unfractionated homogenate Particulate fraction 
pU/ml $J/mU 5’- /rU/ml mU/mg protein pU/mU 5 ‘- 
nucleotidase homogenate nucleotidase 
None 
Insulin 
Cycloheximide 
Cycloheximide 
plus insulin 
8 744.3 + 96.7 2.71+ 0.52 115.3 f 14.3 0.24 f 0.04 1.00+0.12 
8 750.4 f 96.4 2.72 f 0.54 146.0+ 15.4**** 0.30 f 0.03** 1.37&0.16**** 
4 661.7k44.7 2.72 f 0.24 130.9* 17.4 0.20+0.03 0.77*0.13 
4 825.1 -?I 68.8ttt 3.43 * 0.32tttt 175.0* 19.8t 0.28 + 0.02 t 1.00~0.1tt 
Acini were incubated as described in the text, with insulin (1.68 mu/ml) and/or cycloheximide (50 pg/ml) as indicated. 
Values given are means + SE. Statistically significant differences were determined using Student’s t-test for paired 
observations. Asterisks denote values greater than the control (no addition) sample atp<O.O05 (****) or p<O.O25 (**). 
Daggers denote values greater than the ‘plus cycloheximide’ sample at p~O.005 (tttt), p<O.Ol (ttt), ~~0.025 (tt) 
or p<O.O5 (t). 5’ -Nucleotidase values in all homogenates, averaged 242.9 mu/ml. 
AMP (not shown). Homogenates of rat mammary 
tissue and of isolated acini have been shown [22] to 
contain two major kinetic forms of cyclic AMP 
phosphodiesterase, with Ko.5 values for cyclic 
AMP of 1.3 /cM and 21.6 PM. Thus, activity 
measured as in this study at 1 PM cyclic AMP 
(table 1) reflects predominantly the activity of 
those forms of cyclic AMP phosphodiesterase hav- 
ing a high affinity for cyclic AMP. 
Exposure of acini to insulin for a shorter dura- 
tion (15 min) than that used in the above ex- 
periments (60 min) did not in our initial ex- 
periments consistently result in a stimulation of 
cyclic AMP phosphodiesterase (not shown). This 
was unexpected, since the analogous effect in 
hepatocytes and adipocytes is reported to be rapid, 
reaching maximal amplitude in hepatocytes for in- 
stance [ll] within 2-5 min at 37°C. Insulin is 
known to be capable of a generalized stimulation 
of protein synthesis in several cell-types including 
adipocytes (see, e.g. [23]). It seemed possible that 
the apparently ‘slow’ effect of insulin on mam- 
mary cell phosphodiesterase was an expression of 
this aspect of insulin’s action. That this was not so 
was demonstrated by a series of experiments in 
which cycloheximide was included in the incuba- 
tions of mammary acini with and without insulin. 
The protein synthesis inhibitor failed to suppress 
the stimulation by insulin of cyclic AMP 
phosphodiesterase activity; indeed, it significantly 
enhanced this activity (table 1). Qualitative aspects 
of these results were essentially unchanged whether 
enzyme activity data were expressed on a ‘per in- 
cubation’, a ‘per mg protein’ or a ‘per unit of 
5 ’ -nucleotidase activity’ basis. 
4. DISCUSSION 
The physiological role of the stimulation of 
cyclic AMP phosphodiesterase by insulin remains 
the subject of debate. Undoubtedly, such stimula- 
tion does provide a possible mechanism for the 
insulin-mediated reversal of the actions of those 
hormones (e.g. glucagon, adrenaline) which act 
primarily to increase the intracellular concentra- 
tion of cyclic AMP, in that the physiological ef- 
fects of insulin-treatment in both adipocytes and 
hepatocytes are accompanied by a decrease in in- 
tracellular cyclic AMP [24,25]. An analogous ef- 
fect may exist in mammary acini: although 
glucagon and adrenaline are apparently without ef- 
fect on this preparation [17,26,27], theophylline 
has been shown to diminish the rate of lipogenesis 
by acini in vitro [17]. Since this agent is an in- 
hibitor of cyclic nucleotide phosphodiesterases 
[28], its effect on lipogenesis most probably results 
from an increase in the intracellular concentration 
of cyclic AMP. Insulin is able to reverse this 
theophylline-induced inhibition of lipogenesis in 
mammary acini [17]. Thus, this report of the oc- 
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currence of an insulin-stimulated cyclic AMP 
phosphodiesterase in a tissue (mammary gland) in 
which the effects of a lipolytic agent have been 
shown to be reversed by insulin strengthens the 
hypothesis that the two phenomena may be 
mechanistically linked. 
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